![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
429kB |
| Item Type: | Article |
|---|---|
| Title: | Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder |
| Creators Name: | Chavarro, V.S. and Mealy, M.A. and Simpson, A. and Lacheta, A. and Pache, F. and Ruprecht, K. and Gold, S.M. and Paul, F. and Brandt, A.U. and Levy, M. |
| Abstract: | OBJECTIVE: To investigate depression frequency, severity, current treatment, and interactions with somatic symptoms among patients with neuromyelitis optica spectrum disorder (NMOSD). METHODS: In this dual-center observational study, we included 71 patients diagnosed with NMOSD according to the International Panel for NMO Diagnosis 2015 criteria. The Beck Depression Inventory (BDI) was classified into severe, moderate, or minimal/no depressive state category. We used the Fatigue Severity Scale to evaluate fatigue. Scores from the Brief Pain Inventory and the PainDETECT Questionnaire were normalized to estimate neuropathic pain. Psychotropic, pain, and immunosuppressant medications were tabulated by established classes. RESULTS: Twenty-eight percent of patients with NMOSD (n = 20) had BDI scores indicative of moderate or severe depression; 48% of patients (n = 34) endorsed significant levels of neuropathic pain. Severity of depression was moderately associated with neuropathic pain (r = 0.341, p < 0.004) but this relationship was confounded by levels of fatigue. Furthermore, only 40% of patients with moderate or severe depressive symptoms received antidepressant medical treatment. Fifty percent of those treated reported persistent moderate to severe depressive symptoms under treatment. CONCLUSIONS: Moderate and severe depression in patients with NMOSD is associated with neuropathic pain and fatigue and is insufficiently treated. These results are consistent across 2 research centers and continents. Future research needs to address how depression can be effectively managed and treated in NMOSD. |
| Source: | Neurology Neuroimmunology & Neuroinflammation |
| ISSN: | 2332-7812 |
| Publisher: | American Academy of Neurology |
| Volume: | 3 |
| Number: | 6 |
| Page Range: | e286 |
| Date: | December 2016 |
| Official Publication: | https://doi.org/10.1212/NXI.0000000000000286 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
